ReviewCancers2023
The Tissue Factor Pathway in Cancer: Overview and Role of Heparan Sulfate Proteoglycans.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed.
- Protease-Activated Receptor-2 as a Proteolytic Rheostat in Colorectal and Pancreatic Cancer: From Mechanism to Biomarker-Guided Therapy.International journal of molecular sciences · 2026Review
- IMMUNIA: A Reasoning-Centered Framework for Immunoregulatory Surfaceome Discovery.ACS pharmacology & translational science · 2026Article
- Hemostasis at the edge between physiology and cancer.Internal and emergency medicine · 2026Review
- Thrombin Generation Induced by Complement Component C1q Interaction With the Receptor for the Globular Head of C1q on Adventitial Fibroblasts and Vascular Smooth Muscle Cells.Immunity, inflammation and disease · 2026Article
- Emerging roles of haemostatic proteins as markers of disease progression and prognosis in breast cancer.Exploration of targeted anti-tumor therapy · 2026Review
- Hemorrhage-coagulation immune phenotype is associated with CD163/HO-1-enriched heme-processing macrophage remodeling and predicts recurrence in colorectal cancer: a real-world retrospective cohort study.Frontiers in immunology · 2026Article
- Right atrial extension of inferior vena cava thrombosis after microwave ablation of colorectal liver metastasis: a case report.Frontiers in oncology · 2026Article
- D-Dimer Dynamics as a Prognostic and Monitoring Biomarker in Triple-Negative and Metastatic Breast Cancer: A Narrative Review.Breast cancer (Dove Medical Press) · 2026Review
- Venous Thrombogenesis and Cervical Cancer: Plasma MicroRNAs as Prognostic Indicators of Tumor Behavior.International journal of molecular sciences · 2025Article
- The Icarian flight of antibody-drug conjugates: target selection amidst complexity and tackling adverse impacts.Protein & cell · 2025Review
- Targets for CAR Therapy in Multiple Myeloma.International journal of molecular sciences · 2025Review
- Challenges and Opportunities of Direct Oral Anticoagulant (DOAC) Therapy in Complex Clinical Scenarios: A Comprehensive Review and Practical Guide.Journal of clinical medicine · 2025Review
- Article
- Tissue factor targeted near-infrared photoimmunotherapy: a versatile therapeutic approach for malignancies.Cancer immunology, immunotherapy : CII · 2025Article
- Unraveling the role of coagulation-related genes in esophageal squamous cell carcinoma: development of a prognostic model and exploration of potential clinical significance.Frontiers in oncology · 2025Article
- Enhancing Tissue Factor Production: The Role of N-Glycosylation and ERAD Pathway Modulation.Protein and peptide letters · 2025Article
- What is worth knowing about peritoneal metastases in colorectal cancer?Frontiers in surgery · 2025Review
- Immunoconjugates as an Efficient Platform for Drug Delivery: A Resurgence of Natural Products in Targeted Antitumor Therapy.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Low-Grade Activation of the Extrinsic Coagulation Pathway in Patients with Ulcerative Colitis.Digestive diseases and sciences · 2024Article
- Epigenetic Targeting of Heparan Sulfate 3-ACS pharmacology & translational science · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Historically, the only focus on tissue factor (TF) in clinical pathophysiology has been on its function as the initiation of the extrinsic coagulation cascade. This obsolete vessel-wall TF dogma is now being challenged by the findings that TF circulates throughout the body as a soluble form, a cell-associated protein, and a binding microparticle. Furthermore, it has been observed that TF is expressed by various cell types, including T-lymphocytes and platelets, and that certain pathological situations, such as chronic and acute inflammatory states, and cancer, may increase its expression and activity. Transmembrane G protein-coupled protease-activated receptors can be proteolytically cleaved by the TF:FVIIa complex that develops when TF binds to Factor VII (PARs). The TF:FVIIa complex can activate integrins, receptor tyrosine kinases (RTKs), and PARs in addition to PARs. Cancer cells use these signaling pathways to promote cell division, angiogenesis, metastasis, and the maintenance of cancer stem-like cells. Proteoglycans play a crucial role in the biochemical and mechanical properties of the cellular extracellular matrix, where they control cellular behavior via interacting with transmembrane receptors. For TFPI.fXa complexes, heparan sulfate proteoglycans (HSPGs) may serve as the primary receptor for uptake and degradation. The regulation of TF expression, TF signaling mechanisms, their pathogenic effects, and their therapeutic targeting in cancer are all covered in detail here.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.